共 24 条
Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden
被引:32
作者:
Lindmark, Krister
[1
,2
]
Boman, Kurt
[3
]
Olofsson, Mona
[3
]
Tornblom, Michael
[4
]
Levine, Aaron
[4
]
Castelo-Branco, Anna
[4
]
Schlienger, Raymond
[5
]
Wirta, Sara Bruce
[6
]
Stalhammar, Jan
[7
]
Wikstrom, Gerhard
[8
]
机构:
[1] Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90187 Umea, Sweden
[2] Umea Univ Hosp, Heart Ctr, S-90187 Umea, Sweden
[3] Umea Univ, Res Unit, Med Geriatr, Skelleftea Cty Hosp,Dept Publ Hlth & Clin Med, Umea, Sweden
[4] IQVIA, Real World & Analyt Solut, Solna, Sweden
[5] Novartis Pharma AG, Quantitat Safety & Epidemiol, Basel, Switzerland
[6] Novartis Sweden AB, Global RWE Cardiometabol, Stockholm, Sweden
[7] Uppsala Univ, Dept Publ Hlth & Caring Sci, Family Med & Prevent Med, Uppsala, Sweden
[8] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
关键词:
diagnosis;
heart failure;
incidence rate;
mortality;
prevalence;
real-world;
MORTALITY;
HOSPITALIZATION;
IMPACT;
RATES;
D O I:
10.2147/CLEP.S170873
中图分类号:
R1 [预防医学、卫生学];
学科分类号:
1004 ;
120402 ;
摘要:
Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden. Methods: Adults with incident HF (>= 2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005-2013) and electronic medical records (cohort 2, 2010-2015; primary/secondary care patients from Uppsala and Vasterbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed. Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged >= 85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06-1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02-1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997-2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF.
引用
收藏
页码:231 / 244
页数:14
相关论文